{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/102930"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/102930","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Development of intranasal therapeutic nanoparticles for the treatment of neurological disorders","abstract":"Globally, ischemic stroke is a leading cause of both death and adult disability. Current therapeutics emphasize reperfusion without further mechanisms to reduce infarct volume or promote healing and are most effective within 3 h of symptom onset: a window in which less than 30% of stroke victims receive medical attention. Numerous neuroprotective agents, such as peptides, hormones, and siRNA, have been shown to confer neuroprotection following ischemic stroke in animal models. Clinically, treatment of ischemic stroke is hindered by the relative isolation of the central nervous system from the systemic circulation by the blood brain barrier (BBB). Though cannula and intracranial injections are practical methods to circumvent the BBB in laboratory conditions, such procedures are contraindicated in clinical settings. As such, we are interested in leveraging the intranasal (IN) pathway to bridge the gap between animal studies and clinical application. However, the advantages of the IN pathway are tempered by low efficiency, and, therefore, we have applied our gelatin nanoparticle (GNP) technology to aid drug delivery to the brain following IN administration. GNPs are a biodegradable, biocompatible, and cost-effective drug delivery platform. As we have previously demonstrated, GNPs can not only pass into the brain parenchyma following intranasal administration, but also extend and enhance the neuroprotective effects of peptide and siRNA model drugs when administered up to 6 h after middle cerebral artery occlusion (MCAO) in a rat model. The specific properties of intranasal GNPs that confer these beneficial effects are poorly understood. Therefore, we sought to support the development of GNPs as a drug delivery platform for the IN treatment of ischemic stroke and, potentially, other neurological disorders by studying their distribution and degradation. Finally, to further investigate the versatility and therapeutic potential of IN GNPs, we have applied our technology to the delivery of estrogen post-ischemia. The use of estrogens in stroke is a classic example of the disparity between animal and human studies; estrogen replacement therapy has repeatedly failed to show clinical benefit in the prevention of cerebrovascular disease despite extensive preclinical data demonstrating benefits. Therefore, the problem of estrogen in stroke is a particularly poignant test case for our hypothesis that IN GNPs can address disparities between preclinical and clinical studies by providing a patient-friendly drug administration method.","abstract_html":"Globally, ischemic stroke is a leading cause of both death and adult disability. Current therapeutics emphasize reperfusion without further mechanisms to reduce infarct volume or promote healing and are most effective within 3 h of symptom onset: a window in which less than 30% of stroke victims receive medical attention. Numerous neuroprotective agents, such as peptides, hormones, and siRNA, have been shown to confer neuroprotection following ischemic stroke in animal models. Clinically, treatment of ischemic stroke is hindered by the relative isolation of the central nervous system from the systemic circulation by the blood brain barrier (BBB). Though cannula and intracranial injections are practical methods to circumvent the BBB in laboratory conditions, such procedures are contraindicated in clinical settings. As such, we are interested in leveraging the intranasal (IN) pathway to bridge the gap between animal studies and clinical application. However, the advantages of the IN pathway are tempered by low efficiency, and, therefore, we have applied our gelatin nanoparticle (GNP) technology to aid drug delivery to the brain following IN administration. GNPs are a biodegradable, biocompatible, and cost-effective drug delivery platform. As we have previously demonstrated, GNPs can not only pass into the brain parenchyma following intranasal administration, but also extend and enhance the neuroprotective effects of peptide and siRNA model drugs when administered up to 6 h after middle cerebral artery occlusion (MCAO) in a rat model. The specific properties of intranasal GNPs that confer these beneficial effects are poorly understood. Therefore, we sought to support the development of GNPs as a drug delivery platform for the IN treatment of ischemic stroke and, potentially, other neurological disorders by studying their distribution and degradation. Finally, to further investigate the versatility and therapeutic potential of IN GNPs, we have applied our technology to the delivery of estrogen post-ischemia. The use of estrogens in stroke is a classic example of the disparity between animal and human studies; estrogen replacement therapy has repeatedly failed to show clinical benefit in the prevention of cerebrovascular disease despite extensive preclinical data demonstrating benefits. Therefore, the problem of estrogen in stroke is a particularly poignant test case for our hypothesis that IN GNPs can address disparities between preclinical and clinical studies by providing a patient-friendly drug administration method.","abstract_has_math":false,"creators":["Joachim, Elizabeth Grace"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Bioengineering","degree_department":null,"school":null,"contributors":["Kim, Kevin K.","Choi, Hyungsoo","Liang, Zhi-Pei","Bashir, Rashid"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-02-08T18:43:48Z","date_published":"2019-02-08T18:43:48Z","updated_at":"2026-07-22T22:24:42Z","subjects":["neuroprotection","stroke","estrogen","intranasal delivery"],"languages":["en"],"rights":["Copyright 2018 Elizabeth Joachim"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/102930","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Kim, Kevin K.","Choi, Hyungsoo","Liang, Zhi-Pei","Bashir, Rashid"]},{"key":"dc:creator","label":"Author","values":["Joachim, Elizabeth Grace"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019-02-08T18:43:48Z","2021-02-09T10:15:30Z","2018-12-05","2018-12"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Bioengineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["neuroprotection","stroke","estrogen","intranasal delivery"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2018 Elizabeth Joachim"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/102930"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Globally, ischemic stroke is a leading cause of both death and adult disability. Current therapeutics emphasize reperfusion without further mechanisms to reduce infarct volume or promote healing and are most effective within 3 h of symptom onset: a window in which less than 30% of stroke victims receive medical attention. Numerous neuroprotective agents, such as peptides, hormones, and siRNA, have been shown to confer neuroprotection following ischemic stroke in animal models. Clinically, treatment of ischemic stroke is hindered by the relative isolation of the central nervous system from the systemic circulation by the blood brain barrier (BBB). Though cannula and intracranial injections are practical methods to circumvent the BBB in laboratory conditions, such procedures are contraindicated in clinical settings. As such, we are interested in leveraging the intranasal (IN) pathway to bridge the gap between animal studies and clinical application. However, the advantages of the IN pathway are tempered by low efficiency, and, therefore, we have applied our gelatin nanoparticle (GNP) technology to aid drug delivery to the brain following IN administration. GNPs are a biodegradable, biocompatible, and cost-effective drug delivery platform. As we have previously demonstrated, GNPs can not only pass into the brain parenchyma following intranasal administration, but also extend and enhance the neuroprotective effects of peptide and siRNA model drugs when administered up to 6 h after middle cerebral artery occlusion (MCAO) in a rat model. The specific properties of intranasal GNPs that confer these beneficial effects are poorly understood. Therefore, we sought to support the development of GNPs as a drug delivery platform for the IN treatment of ischemic stroke and, potentially, other neurological disorders by studying their distribution and degradation. Finally, to further investigate the versatility and therapeutic potential of IN GNPs, we have applied our technology to the delivery of estrogen post-ischemia. The use of estrogens in stroke is a classic example of the disparity between animal and human studies; estrogen replacement therapy has repeatedly failed to show clinical benefit in the prevention of cerebrovascular disease despite extensive preclinical data demonstrating benefits. Therefore, the problem of estrogen in stroke is a particularly poignant test case for our hypothesis that IN GNPs can address disparities between preclinical and clinical studies by providing a patient-friendly drug administration method.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2020-12-01","The student, Elizabeth Joachim, accepted the attached license on 2018-12-03 at 11:17.","The student, Elizabeth Joachim, submitted this Dissertation for approval on 2018-12-03 at 11:29.","This Dissertation was approved for publication on 2018-12-05 at 14:20.","DSpace SAF Submission Ingestion Package generated from Vireo submission #13176 on 2019-02-08 at 11:40:45","Made available in DSpace on 2019-02-08T18:43:48Z (GMT). No. of bitstreams: 2 JOACHIM-DISSERTATION-2018.pdf: 12326200 bytes, checksum: a05188f8ab7ff6bf6f6a7cb501c3d61a (MD5) LICENSE.txt: 4214 bytes, checksum: 93902aac9a1aa5e4225bddccd8c2f3b8 (MD5) Previous issue date: 2018-12-05","Embargo set by: Seth Robbins for item 109957 Lift date: 2021-02-08T18:43:54Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 109957 Lift date: 2021-02-08T18:44:50Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 109957 on 2021-02-09T10:15:30Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Development of intranasal therapeutic nanoparticles for the treatment of neurological disorders"]}]}],"canonical_facts":{"dc:contributor":["Kim, Kevin K.","Choi, Hyungsoo","Liang, Zhi-Pei","Bashir, Rashid"],"dc:creator":["Joachim, Elizabeth Grace"],"dc:date":["2019-02-08T18:43:48Z","2021-02-09T10:15:30Z","2018-12-05","2018-12"],"dc:description":["Globally, ischemic stroke is a leading cause of both death and adult disability. Current therapeutics emphasize reperfusion without further mechanisms to reduce infarct volume or promote healing and are most effective within 3 h of symptom onset: a window in which less than 30% of stroke victims receive medical attention. Numerous neuroprotective agents, such as peptides, hormones, and siRNA, have been shown to confer neuroprotection following ischemic stroke in animal models. Clinically, treatment of ischemic stroke is hindered by the relative isolation of the central nervous system from the systemic circulation by the blood brain barrier (BBB). Though cannula and intracranial injections are practical methods to circumvent the BBB in laboratory conditions, such procedures are contraindicated in clinical settings. As such, we are interested in leveraging the intranasal (IN) pathway to bridge the gap between animal studies and clinical application. However, the advantages of the IN pathway are tempered by low efficiency, and, therefore, we have applied our gelatin nanoparticle (GNP) technology to aid drug delivery to the brain following IN administration. GNPs are a biodegradable, biocompatible, and cost-effective drug delivery platform. As we have previously demonstrated, GNPs can not only pass into the brain parenchyma following intranasal administration, but also extend and enhance the neuroprotective effects of peptide and siRNA model drugs when administered up to 6 h after middle cerebral artery occlusion (MCAO) in a rat model. The specific properties of intranasal GNPs that confer these beneficial effects are poorly understood. Therefore, we sought to support the development of GNPs as a drug delivery platform for the IN treatment of ischemic stroke and, potentially, other neurological disorders by studying their distribution and degradation. Finally, to further investigate the versatility and therapeutic potential of IN GNPs, we have applied our technology to the delivery of estrogen post-ischemia. The use of estrogens in stroke is a classic example of the disparity between animal and human studies; estrogen replacement therapy has repeatedly failed to show clinical benefit in the prevention of cerebrovascular disease despite extensive preclinical data demonstrating benefits. Therefore, the problem of estrogen in stroke is a particularly poignant test case for our hypothesis that IN GNPs can address disparities between preclinical and clinical studies by providing a patient-friendly drug administration method.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2020-12-01","The student, Elizabeth Joachim, accepted the attached license on 2018-12-03 at 11:17.","The student, Elizabeth Joachim, submitted this Dissertation for approval on 2018-12-03 at 11:29.","This Dissertation was approved for publication on 2018-12-05 at 14:20.","DSpace SAF Submission Ingestion Package generated from Vireo submission #13176 on 2019-02-08 at 11:40:45","Made available in DSpace on 2019-02-08T18:43:48Z (GMT). No. of bitstreams: 2 JOACHIM-DISSERTATION-2018.pdf: 12326200 bytes, checksum: a05188f8ab7ff6bf6f6a7cb501c3d61a (MD5) LICENSE.txt: 4214 bytes, checksum: 93902aac9a1aa5e4225bddccd8c2f3b8 (MD5) Previous issue date: 2018-12-05","Embargo set by: Seth Robbins for item 109957 Lift date: 2021-02-08T18:43:54Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 109957 Lift date: 2021-02-08T18:44:50Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 109957 on 2021-02-09T10:15:30Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/102930"],"dc:language":["en"],"dc:rights":["Copyright 2018 Elizabeth Joachim"],"dc:subject":["neuroprotection","stroke","estrogen","intranasal delivery"],"dc:title":["Development of intranasal therapeutic nanoparticles for the treatment of neurological disorders"],"dc:type":["text"],"thesis:degree_discipline":["Bioengineering"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:42Z"}